Search
Iron isomaltoside 1000
go.drugbank.com/drugs/DB12208ApprovedInvestigationalWithdrawnIron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalPanitumumab was granted FDA approval on 27 September 2006.[L17663]
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653]
Dengue virus serotype 1
go.drugbank.com/drugs/DB22664Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Cefapirin
go.drugbank.com/drugs/DB01139ApprovedVet approvedProduction for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Capromab pendetide
go.drugbank.com/drugs/DB00089ApprovedWithdrawnWhen linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. … Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate
Pentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedA short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.
Interferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalIt is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.
VTP-201227
go.drugbank.com/drugs/DB05652ExperimentalVTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.